Earnings Call Summary | TERUMO CORP(TRUMF.US) Q3 2024 Earnings Conference
Earnings Call Summary | TERUMO CORP(TRUMF.US) Q3 2024 Earnings Conference
The following is a summary of the Terumo Corporation (TRUMF) Q3 2024 Earnings Call Transcript:
以下是Terumo Corporation（TRUMF）2024年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Terumo Corporation reported highest ever revenue in Q3 2024 due to double-digit growth in revenue, operating profit, and annual profit.
Profits grew by 9% YoY excluding FX.
Factors such as price increases, profitability improvement measures, and inflation ease drove increase in operating profit.
Gross profit increased beyond expected, even with increased SG&A factors like price policy revision and bolstered sales force in North America.
Terumo Corporation報告稱，由於收入、營業利潤和年利潤的兩位數增長，2024年第三季度收入創歷史新高。
不包括外匯，利潤同比增長9％。
價格上漲、盈利能力改善措施和通貨膨脹緩解等因素推動了營業利潤的增長。
儘管價格政策修訂和北美銷售隊伍增強等銷售和收購因素有所增加，但毛利增長仍超出預期。
Business Progress:
業務進展：
Revenue was mainly driven by TIS and Vascular Graft businesses of the Cardiac and Vascular Company and blood center business of the Blood and Cell Technologies Company.
Expansion of therapeutic devices in North America is evident by the shift from negative to positive gross margin in H2.
While therapeutic devices remain strong in main markets, emerging markets like Asia and The Middle East also contributed to growth rate.
Volume-based procurement in China impacted Q3.
Annual guidance has been revised upward especially for Cardiac and Vascular, and Blood and Cell Technologies predicting a continued profitability improvement in Q4 despite a downward revision of Medical Care Solutions.
收入主要由心臟和血管公司的TIS和血管移植業務以及血液和細胞技術公司的血液中心業務推動。
下半年毛利率從負向正的轉變爲正數，北美治療設備的擴張是明證。
儘管主要市場的治療設備仍然強勁，但亞洲和中東等新興市場也推動了增長率。
中國基於數量的採購影響了第三季度。
年度預期已向上修正，尤其是心臟和血管以及血液和細胞技術公司的年度指引，儘管醫療保健解決方案向下修正，但第四季度的盈利能力仍將持續改善。
More details: TERUMO CORP IR
更多詳情： TERUMO CORP IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。